Barmherzige Brueder Trier gGmbH — Clinical Trial Site

41 Registered trials

21 Currently recruiting

Organisation

Barmherzige Brueder Trier gGmbH

Location

Trier, Germany

Identifier

ORG-100022106

Address

Nordallee 1, Trier-Nord, 54292, Germany

Departments

2619: Abteilung für Urologie und Kinderurologie, Institut für Lithotripsie
Abteilung für Innere Medizin I
Abteilung für Innere Medizin III/Kardiologie
Abteilung für Neurologie
Abteilung für Urologie und Kinderurologie
Abteilung für Urologie und Kinderurologie Institut für Lithotripsie
Abteilung Innere Medizin I
Barmherzige Brueder Trier gGmbH
Gastroentereologie, Hämatologie/Internistische Onkologie und Infektiologie
Hämatologie und internistische Onkologie
Hämatologie und Onkologie Innere Medizin I
Hämatologisches Zentrum
Hematology
Herz- und Thoraxchirurgie
Herzzentrum Trier
Herzzentrum Trier Innere Medizin III - Kardiologie
I. Medizinische Abteilung
I. Medizinische Abteilung Sektion Hämatologie und Internistische Onkologie
I. Medizinische Abteilung Sektion Hämatologie/ internistische Onkologie
Innere Medizin I
Innere Medizin II
Innere Medizin IV
Interventionelle Kardiologie
Klinik für Innere Medizin II
Krankenhaus der Barmherzigen Brüder, Innere Medizin II
Medical Clinic IV, Respiratory Medicine
NA
Neurologie und Neurophysiologie
Neurology
Onkologisches Zentrum
Urologie und Kinderurologie

Clinical trials at this site (41)

Search interface

A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl… Pending

2024-519638-22-00 IgA nephropathy 5
A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) Recruiting

2024-519521-37-01 Acute ischemic stroke 10 2025-07-30
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 AF patients who have undergone successful PCI 5 2024-12-16
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting

2024-512320-11-00 Primary diffuse large B-cell lymphoma of the central ne 5 2023-08-09
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with… Recruiting

2024-515924-35-00 New-Onset Post-Operative Atrial Fibrillation after CABG 6 2023-01-16
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or … Recruiting

2023-507461-26-00 Newly diagnosed acute myeloid leukemia (AML) 5 2022-09-22
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli… Recruiting

2024-512953-26-00 intermediate-stage hepatocellular carcinoma 5 2021-07-06
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended

2022-502634-52-00 prostate cancer 5 2023-05-16